PDS Biotechnology Toekomstige groei
Future criteriumcontroles 0/6
De verwachting is dat PDS Biotechnology de winst en omzet met respectievelijk 44.9% en 66% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 48% per jaar.
Belangrijke informatie
44.9%
Groei van de winst
48.00%
Groei van de winst per aandeel
| Biotechs winstgroei | 25.5% |
| Inkomstengroei | 66.0% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 13 May 2026 |
Recente toekomstige groei-updates
Recent updates
Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?
Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience
Catalysts About PDS Biotechnology PDS Biotechnology is a clinical stage company developing immunotherapy treatments for HPV16 positive cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?
HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapies for HPV16-positive head and neck cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Summary PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy targeting the p16 protein found in HPV16-infected cells in head and neck cancer. PDSB has shown promising clinical data, with a 74% 2-year overall survival rate in a phase 2 study, but their cash position is a concern. Read the full article on Seeking AlphaPDS Biotech jumps 13% as FDA clears further development of lead asset
PDS Biotechnology (NASDAQ:PDSB), a biopharma focused on cancer immunotherapies, added 13% pre-market Monday after the company announced that a recent End-of-Phase 2 meeting with the FDA brought clarity to the late-stage development of its lead asset PDS0101. At the meeting, PDSB has submitted interim data to indicate the potential of PDS0101 against a particular form of head and neck squamous cell carcinoma (HNSCC) in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda. "The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule," Chief Executive Frank Bedu-Addo remarked. The FDA has issued Fast Track designation to PDS0101/ Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer.PDS Biotechnology files for $150 mixed shelf offering
PDS Biotechnology Corp. (NASDAQ:PDSB) has filed for a $150 mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercialization of product candidates and general corporate purposes. Separately, PDS Biotechnology (PDSB) said it entered into a debt financing agreement led by Horizon Technology Finance Corporation (HRZN) for up to $35M. Seeking Alpha's Quant Rating views PDS Biotechnology (PDSB) as a hold.PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
PDS Biotechnology (NASDAQ:PDSB) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda be continued without changes. The decision of the independent Data Monitoring Committee (DMC) was based on safety data from the study which is designed to study PDS0101 and Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer. The DMC analysis of 43 patients indicated that there were no drug discontinuations related to toxicity or treatment related Grade 3 or greater adverse events, according to the company. In May, PDS Biotech (PDSB) announced that U.K. regulators accepted its application seeking to conduct the VERSATILE-002 trial in that country.PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients. Proof of concept for PDS Biotechnology's Versamune T-cell activating technology platform was established. PDS Biotechnology had $58.9 million in cash as of March 31, 2022; enough cash to fund its operations into 2024.PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity). The company has an enterprise value of just $125M. The stock has near-term catalysts this year and is at a good buy level.Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 2 | -35 | -46 | N/A | 2 |
| 12/31/2027 | N/A | -35 | -39 | N/A | 2 |
| 12/31/2026 | N/A | -31 | -30 | N/A | 2 |
| 3/31/2026 | N/A | -33 | N/A | N/A | N/A |
| 12/31/2025 | N/A | -34 | -28 | -28 | N/A |
| 9/30/2025 | N/A | -35 | -32 | -32 | N/A |
| 6/30/2025 | N/A | -37 | -34 | -34 | N/A |
| 3/31/2025 | N/A | -35 | -34 | -34 | N/A |
| 12/31/2024 | N/A | -38 | -35 | -35 | N/A |
| 9/30/2024 | N/A | -41 | -35 | -35 | N/A |
| 6/30/2024 | N/A | -41 | -34 | -34 | N/A |
| 3/31/2024 | N/A | -44 | -30 | -30 | N/A |
| 12/31/2023 | N/A | -43 | -34 | -34 | N/A |
| 9/30/2023 | N/A | -51 | -33 | -33 | N/A |
| 6/30/2023 | N/A | -48 | -31 | -31 | N/A |
| 3/31/2023 | N/A | -42 | -33 | -33 | N/A |
| 12/31/2022 | N/A | -41 | -26 | -26 | N/A |
| 9/30/2022 | N/A | -28 | -23 | -23 | N/A |
| 6/30/2022 | N/A | -28 | -22 | -22 | N/A |
| 3/31/2022 | N/A | -22 | -15 | -15 | N/A |
| 12/31/2021 | N/A | -17 | -12 | -12 | N/A |
| 9/30/2021 | N/A | -15 | -13 | -13 | N/A |
| 6/30/2021 | N/A | -12 | -9 | -9 | N/A |
| 3/31/2021 | N/A | -14 | -14 | -14 | N/A |
| 12/31/2020 | N/A | -15 | -13 | -13 | N/A |
| 9/30/2020 | N/A | -15 | -14 | -14 | N/A |
| 6/30/2020 | N/A | -17 | -17 | -17 | N/A |
| 3/31/2020 | N/A | -18 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -7 | N/A | -18 | N/A |
| 9/30/2019 | N/A | -5 | N/A | -13 | N/A |
| 6/30/2019 | N/A | 0 | N/A | -9 | N/A |
| 3/31/2019 | N/A | 4 | N/A | -5 | N/A |
| 12/31/2018 | N/A | -4 | N/A | -2 | N/A |
| 9/30/2018 | N/A | -2 | N/A | -2 | N/A |
| 12/31/2017 | N/A | -3 | N/A | -3 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat PDSB de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat PDSB de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat PDSB de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: Er wordt verwacht dat PDSB volgend jaar geen omzet zal hebben.
Hoge groei-inkomsten: Er wordt verwacht dat PDSB volgend jaar geen omzet zal hebben.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PDSB naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 21:37 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
PDS Biotechnology Corporation wordt gevolgd door 5 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |